Art. -Nr.: HY-13259C

(R)-MG-132

(Synonyms: (S,R,S)-(-)-MG-132; Z-Leu-D-Leu-Leu-al)

18 Cited Publications

Kundenbewertung

Based on 18 publication(s) in Google Scholar

(R)-MG-132 ((S,R,S)-(-)-MG-132) is the enantiomer of MG-132. (R)-MG-132 is a proteasome inhibitor with weaker cell cytotoxicity than MG-132.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.89%
CAS. Nr.: 1211877-36-9
Formel: C₂₆H₄₁N₃O₅
Molecular Weight:475.62

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

(R)-MG-132 Chemical Structure

CAS. Nr.: 1211877-36-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
Chemical Information
Publications (18)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

(R)-MG-132 ((S,R,S)-(-)-MG-132) is the enantiomer of MG-132. (R)-MG-132 is a proteasome inhibitor with weaker cell cytotoxicity than MG-132^[1].

IC₅₀ & Target

Proteasome^[1]

In Vitro

(R)-MG-132, the stereoisomer of MG-132, is studied as a potential inhibitor of chymotrypsin-like, trypsin-like, and peptidylglutamyl peptide hydrolyzing activities of proteasome^[1].
MG-132 and (R)-MG-132 are investigated for inhibition of ChTL, trypsin-like (TL) and peptidylglutamyl peptide hydrolyzing (PGPH) activities of purified 20S proteasomes isolated from human erythrocytes. For MG-132, the IC₅₀s of 0.89 μM, 104.43 μM, and 5.7 μM for ChTL, TL, and PGPH, respectively. For (R)-MG-132, the IC₅₀s of 0.22 μM, 34.4 μM, and 2.95 μM for ChTL, TL, and PGPH, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 1211877-36-9
Appearance Solid
Molecular Weight 475.62
Formel C₂₆H₄₁N₃O₅
Color White to off-white
SMILES

O=C(N[C@H](CC(C)C)C(N[C@@H](CC(C)C)C=O)=O)[C@H](CC(C)C)NC(OCC1=CC=CC=C1)=O
Synonyms

(S,R,S)-(-)-MG-132; Z-Leu-D-Leu-Leu-al
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (18)

All WB

Sort by:

Journal Impact Factor

Nat Commun

Epigenetic compartmentalization of mitotic chromosomes by phase-separation-driven repulsion between WDR5 and the chromosomal passenger complex. [Abstract]

2026 Jun 16. PMID: 42303627
Nat Commun

Phenazine biosynthesis-like domain-containing protein (PBLD) and Cedrelone promote antiviral immune response by activating NF-ĸB. [Abstract]

2025 Jan 8;16(1):496. PMID: 39779683
Adv Sci (Weinh)

PBLD Orchestrates the STING-Mediated Antiviral Immune Response and Autoimmune Diseases. [Abstract]

2025 Nov 8:e14512. PMID: 41204829

(R)-MG-132 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 8:e14512. [Abstract]

Western blotting analysis showed the expression of specified proteins in HSV-1-infected control or PBLD-silenced HeLa cells treated with Z-VAD-FMK (20 µM), MG132 (10 µg/mL), or CQ (50 nM) for 12 h.

(R)-MG-132 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 8:e14512. [Abstract]

The HeLa cells were transfected with the indicated vectors for 36 h and treated with MG132, followed by co-IP analysis.
Nat Struct Mol Biol

Structural basis for STAT2 suppression by flavivirus NS5. [Abstract]

2020 Oct;27(10):875-885. PMID: 32778820

(R)-MG-132 purchased from MedChemExpress. Usage Cited in: Nat Struct Mol Biol. 2020 Oct;27(10):875-885. [Abstract]

Immunoblot analysis of 293T cells transfected with indicated plasmids encoding wild-type or mutant NS5-HAs was performed using antibodies against HA, hSTAT2, and GAPDH, and the cells were incubated with or without proteasome inhibitor MG132 (10 nM; 36 h).
Proc Natl Acad Sci U S A

2026 Feb 5.
Oncogene

TMEM65 promotes gastric tumorigenesis by targeting YWHAZ to activate PI3K-Akt-mTOR pathway and is a therapeutic target. [Abstract]

2024 Mar;43(13):931-943. PMID: 38341472

(R)-MG-132 purchased from MedChemExpress. Usage Cited in: Oncogene. 2024 Mar;43(13):931-943. [Abstract]

MG132 (10 μM; 12 h). TMEM65 decreased YWHAZ ubiquitination and increased its protein level.
Cancer Cell Int

DAPK enhances DDX20 protein stability via suppression of TRIM25-mediated ubiquitination-based DDX20 degradation. [Abstract]

2024 Nov 18;24(1):382. PMID: 39558224

(R)-MG-132 purchased from MedChemExpress. Usage Cited in: Cancer Cell Int. 2024 Nov 18;24(1):382. [Abstract]

MG132 (20 μM; 8 h). Western blot analysis showed the levels of DDX20 in 293T cells with control (SCR shRNA) or knockdown of TRIM25. The relative DDX20 protein level was illustrated graphically.

(R)-MG-132 purchased from MedChemExpress. Usage Cited in: Cancer Cell Int. 2024 Nov 18;24(1):382. [Abstract]

Effect of HA-DAPK overexpression on the ubiquitination of endogenous DDX20 in 293T cells. Whole cell lysates (containing HA-DAPK) were immunoprecipitated using an anti-DDX20 antibody and blotted with an anti-Ubiquitin antibody. The working concentration of MG132 was 20 μM for 8 h.
Virulence

Differential roles of HSP70 and HSP90 in Senecavirus A infection: IRES-dependent translational regulation and viral replication mechanisms. [Abstract]

2026 Dec;17(1):2605380. PMID: 41412139
mBio

TRIM25 promotes antiviral innate immune response by stabilizing IRF7 and its nuclear translocation. [Abstract]

2026 May 13;17(5):e0047026. PMID: 41919938
Biochim Biophys Acta Mol Basis Dis

N6-methyladenosine dynamics in placental development and trophoblast functions, and its potential role in placental diseases. [Abstract]

2024 Jun 10:167290. PMID: 38866113
PLoS Pathog

ARCN1 suppresses innate immune responses against respiratory syncytial virus by promoting STUB1-mediated IKKε degradation. [Abstract]

2025 Dec 4;21(12):e1013751. PMID: 41343552
Sci Rep

GYY4137 ameliorates blood brain barrier damage by inhibiting autophagy mediated occludin degradation in cardiac arrest and resuscitation. [Abstract]

2025 Jan 6;15(1):905. PMID: 39762518
Sci Rep

CISD3 is a prognostic biomarker and therapeutic target in pan-cancer. [Abstract]

2024 Oct 8;14(1):23494. PMID: 39379442
PLoS Pathog

BAG6 inhibits influenza A virus replication by inducing viral polymerase subunit PB2 degradation and perturbing RdRp complex assembly. [Abstract]

2024 Mar 18;20(3):e1012110. PMID: 38498560
Vet Microbiol

Sanguinarine inhibits bovine parainfluenza virus type 3 replication through CD97 suppression. [Abstract]

2025 Oct 20:311:110776. PMID: 41135374
bioRxiv

2025 Sep 15.
Oxid Med Cell Longev

Trophoblast Exosomal UCA1 Induces Endothelial Injury through the PFN1-RhoA/ROCK Pathway in Preeclampsia: A Human-Specific Adaptive Pathogenic Mechanism. [Abstract]

2022 Sep 15;2022:2198923. PMID: 36160709
University of California

2020 Oct.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (210.25 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1025 mL

10.5126 mL

21.0252 mL

5 mM

0.4205 mL

2.1025 mL

4.2050 mL

10 mM

0.2103 mL

1.0513 mL

2.1025 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (5.26 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.26 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 0.83 mg/mL (1.75 mM); Clear solution

This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (272 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Mroczkiewicz M, et al. Studies of the synthesis of all stereoisomers of MG-132 proteasome inhibitors in the tumor targeting approach. J Med Chem. 2010 Feb 25;53(4):1509-18. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1025 mL	10.5126 mL	21.0252 mL	52.5630 mL
	5 mM	0.4205 mL	2.1025 mL	4.2050 mL	10.5126 mL
	10 mM	0.2103 mL	1.0513 mL	2.1025 mL	5.2563 mL
	15 mM	0.1402 mL	0.7008 mL	1.4017 mL	3.5042 mL
	20 mM	0.1051 mL	0.5256 mL	1.0513 mL	2.6281 mL
	25 mM	0.0841 mL	0.4205 mL	0.8410 mL	2.1025 mL
	30 mM	0.0701 mL	0.3504 mL	0.7008 mL	1.7521 mL
	40 mM	0.0526 mL	0.2628 mL	0.5256 mL	1.3141 mL
	50 mM	0.0421 mL	0.2103 mL	0.4205 mL	1.0513 mL
	60 mM	0.0350 mL	0.1752 mL	0.3504 mL	0.8760 mL
	80 mM	0.0263 mL	0.1314 mL	0.2628 mL	0.6570 mL
	100 mM	0.0210 mL	0.1051 mL	0.2103 mL	0.5256 mL

Keywords

(R)-MG-132

18 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

(R)-MG-132

MCE Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) (R)-MG-132

Biologische Aktivität

Chemical Information

Publications (18)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

(R)-MG-132

MCE Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) (R)-MG-132

Biologische Aktivität

Chemical Information

Publications (18)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

(R)-MG-132 Related Classifications

HY-13259C Related Classifications